logo-loader
viewCytoDyn Inc.

Full interview: CytoDyn reports early but strong clinical responses for two patients

CytoDyn (OTCQB:CYDY) President Nader Pourhassan joined Steve Darling from Proactive Vancouver to discuss continued promising clinical responses from its metastatic triple-negative breast Phase1b/2 trial and its trial investigating leronlimab for the treatment of metastatic breast cancer. 

Pourhassan discussed what this all means and also the status of their BLA filing for final approval. 

Quick facts: CytoDyn Inc.

Price: 1.085 USD

OTCQB:CYDY
Market: OTCQB
Market Cap: $467.37 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: CytoDyn sees 'strong result' in leronlimab dose escalation...

CytoDyn Inc (OTCMKTS:CYDY) CEO Dr Nader Pourhassan tells Proactive the biotech's HIV monotherapy dose escalating trial with its flagship drug leronlimab (PRO 140) topped expectations. Dr Pourhassan says patients receiving 525 mg achieved a 'strong result' with a 94% response rate. 

on 14/8/19

2 min read